Hankang Capital
VC Fund
Shanghai, China
Hankang Capital is an investment firm.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 34%
Last updated:
For AI agents: llms.txt
Industries Hankang Capital invests in
Stages Hankang Capital invests in
Countries Hankang Capital invests in
Investment Focus
Industry
- Health Care 9 (31%)
- Biotechnology 8 (28%)
- Pharmaceutical 7 (24%)
- Medical 6 (21%)
- Therapeutics 5 (17%)
Stage
- Series B 8 (28%)
- Series A 5 (17%)
- Series C 2 (7%)
- Seed 1 (3%)
- Series D 1 (3%)
Country
- China 15 (52%)
- United States 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Microtide Biotechnology
|
Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M / Series A / Apr 29, 2026 | |
Pinnacle Medicines
|
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M / Series B / Mar 26, 2026 | |
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $35M / Seed / Jan 30, 2026 | |
Lingtai Biotechnology
|
Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs. | $28.4M / Series B / Dec 18, 2025 | |
Phrontline Biopharma
|
Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M / Seed / Nov 21, 2025 | |
AusperBio
|
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M / Series B / Sep 21, 2025 | |
VelaVigo
|
VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $60M / Seed / Jul 28, 2025 | |
Leto Laboratories
|
Leto Laboratories is a manufacturer of protein products. | Series C / Jul 23, 2025 | |
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $27.8M / Angel / Jun 04, 2025 | |
|
AusperBio
|
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M / Series B / May 28, 2025 | |
| See all 29 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hankang Capital invest in?
Hankang Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 29 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hankang Capital last invest?
The most recent investment recorded for Hankang Capital closed in Apr 2026. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
